Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation

NCT06892223 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukaemia
MDS (Myelodysplastic Syndrome)
MPN (Myeloproliferative Neoplasms)

Interventions

DRUG: Monalizumab (anti-NKG2A monoclonal antibody)

Sponsor

Istituto Clinico Humanitas